Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

ALK-Abelló A/S

Healthcare US AKBLF

38.89USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

31.3531.35
LowHigh

52 Week Range

19.7436.10
LowHigh

Fundamentals

  • Previous Close 38.89
  • Market Cap6945.99M
  • Volume105
  • P/E Ratio36.88
  • Dividend Yield5.10%
  • EBITDA1900.00M
  • Revenue TTM6312.00M
  • Revenue Per Share TTM28.49
  • Gross Profit TTM 4244.00M
  • Diluted EPS TTM0.85

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1631.30M 1057.00M 647.00M 447.00M 279.00M
Minority interest - - - - -
Net income 1194.29M 815.00M 486.00M 335.00M 219.00M
Selling general administrative 1899.00M 369.00M 331.00M 276.00M 240.00M
Selling and marketing expenses - 1564.00M 1422.00M 1381.00M 1234.00M
Gross profit 4148.58M 3552.00M 3035.00M 2791.00M 2396.00M
Reconciled depreciation 328.00M 272.00M 245.00M 238.00M 242.00M
Ebit 1659.23M 1122.00M 669.00M 473.00M 322.00M
Ebitda 1976.51M 1394.00M 913.00M 709.00M 544.00M
Depreciation and amortization 317.28M 272.00M 244.00M 236.00M 222.00M
Non operating income net other - - - - -
Operating income 1659.23M 1091.00M 666.00M 470.00M 292.00M
Other operating expenses 4638.47M 4446.00M 4158.00M 4041.00M 3624.00M
Interest expense 22.95M 65.00M 22.00M 24.00M 23.00M
Tax provision 438.00M 242.00M 161.00M 112.00M 60.00M
Interest income 28.00M 61.00M 12.00M 4.00M 1.00M
Net interest income -3.00000M -4.00000M -10.00000M -20.00000M -22.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 437.01M 242.00M 161.00M 112.00M 60.00M
Total revenue 6297.70M 5537.00M 4824.00M 4511.00M 3916.00M
Total operating expenses 2489.35M 2461.00M 2369.00M 2321.00M 2104.00M
Cost of revenue 2149.12M 1985.00M 1789.00M 1720.00M 1520.00M
Total other income expense net -27.93658M -34.00000M -19.00000M -23.00000M -13.00000M
Discontinued operations - - - - -
Net income from continuing ops 1197.00M 815.00M 486.00M 335.00M 219.00M
Net income applicable to common shares - - - 335.00M 219.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9151.22M 8246.00M 6726.00M 6308.00M 5830.00M
Intangible assets 1307.03M 1329.00M 212.00M 182.00M 165.00M
Earning assets - - - - -
Other current assets 131.70M 128.00M 255.00M - -
Total liab 2720.82M 2873.00M 2279.00M 2320.00M 2350.00M
Total stockholder equity 6430.40M 5373.00M 4447.00M 3988.00M 3480.00M
Deferred long term liab - - - - -
Other current liab 1112.33M 801.00M 747.00M 1001.00M 989.00M
Common stock 110.75M 111.00M 111.00M 111.00M 111.00M
Capital stock 111.00M 111.00M 111.00M 111.00M 111.00M
Retained earnings 6068.22M 5197.00M 4354.00M 3857.00M 3410.00M
Other liab - - - 492.00M 536.00M
Good will 453.97M 463.00M 459.00M 460.00M 457.00M
Other assets - - - 1003.00M 991.00M
Cash 1237.19M 589.00M 474.00M 221.00M 194.00M
Cash and equivalents - - - - -
Total current liabilities 1325.99M 1949.00M 1314.00M 1399.00M 1385.00M
Current deferred revenue 10.98M - 4.00M - -
Net debt -819.19133M 598.00M 291.00M 475.00M 516.00M
Short term debt 63.00M 736.00M 326.00M 267.00M 281.00M
Short long term debt 17.00M 690.00M 280.00M 226.00M 244.00M
Short long term debt total 418.00M 1187.00M 765.00M 696.00M 710.00M
Other stockholder equity - 65.00M -36.00000M 20.00M -41.00000M
Property plant equipment - - - 2018.00M 1814.00M
Total current assets 4483.82M 3294.00M 2968.00M 2645.00M 2403.00M
Long term investments - - - - -
Net tangible assets - - - 3346.00M 2858.00M
Short term investments - - - - -
Net receivables 1335.97M 861.00M 816.00M 764.00M 691.00M
Long term debt 151.00M 166.00M 184.00M 203.00M 222.00M
Inventory 1778.96M 1716.00M 1423.00M 1297.00M 1204.00M
Accounts payable 139.68M 165.00M 128.00M 131.00M 115.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 251.43M 65.00M -18.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 180.59M 171.00M 906.00M 287.00M 201.00M
Deferred long term asset charges - - - - -
Non current assets total 4667.40M 4952.00M 3758.00M 3663.00M 3427.00M
Capital lease obligations 250.00M 331.00M 301.00M 267.00M 244.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -15.00000M -1417.00000M -375.00000M -351.00000M -3.00000M
Change to liabilities - - - 11.00M 61.00M
Total cashflows from investing activities -384.12795M -1417.00000M - -351.00000M -266.00000M
Net borrowings -688.00000M 392.00M - -73.00000M -270.00000M
Total cash from financing activities -758.27856M 310.00M -31.00000M -42.00000M -311.00000M
Change to operating activities - - - - -
Net income 1194.29M 815.00M 486.00M 335.00M 219.00M
Change in cash 718.82M 115.00M 253.00M 27.00M -104.00000M
Begin period cash flow 518.37M 474.00M 221.00M 194.00M 298.00M
End period cash flow 1237.19M 589.00M 474.00M 221.00M 194.00M
Total cash from operating activities 1812.88M 1213.00M 667.00M 416.00M 468.00M
Issuance of capital stock -26.00000M -32.00000M -20.00000M 31.00M 41.00M
Depreciation 317.28M 272.00M 244.00M 238.00M 242.00M
Other cashflows from investing activities -14.96602M -1043.00000M - - -
Dividends paid - - - - -
Change to inventory -125.71460M -272.00000M -132.00000M -74.00000M -84.00000M
Change to account receivables -388.11889M 78.00M -69.00000M -172.00000M -5.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -45.89581M -50.00000M -46.00000M -351.00000M -266.00000M
Change to netincome - - - 80.00M 55.00M
Capital expenditures 275.37M 1303.00M 379.00M 353.00M 263.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -148.66251M -151.00000M -201.00000M -235.00000M -28.00000M
Stock based compensation 45.00M 51.00M 30.00M 27.00M 36.00M
Other non cash items 201.54M 226.00M 108.00M 29.00M 62.00M
Free cash flow 1537.51M -90.00000M 288.00M 63.00M 205.00M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKBLF
ALK-Abelló A/S		 - -% 38.89 36.88 62.50 1.10 6.85 7.70 24.39
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

ALK-Abelló A/S

Bøge Allé 6-8, Horsholm, Denmark, 2970

Key Executives

Name Title Year Born
Mr. Carsten Hellmann Pres, CEO & Member of Management Board 1964
Mr. Soren Jelert Group CFO, Exec. VP & Member of Management Board 1972
Mr. Henrik Jacobi Exec. VP of R&D and Member of Board of Management 1965
Mr. Søren Daniel Niegel Exec. VP of Commercial Operations & Member of Management Board 1971
Ms. Katja Barnkob Thalund Project Director of Global CMC Devel. & Employee-elected Director 1969
Mr. Per Plotnikof VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR NA
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Sr. VP of Research & Devel. - North America and International Markets NA
Mr. Christian G. Houghton Head of Product Supply NA
Mr. Miles Guralnick Pres of ALK Abelló Source Materials Inc NA
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.